HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).

Abstract
Dimebon (latrepirdine) is an anti-histaminergic agent which belongs to a fast-growing group of "old" medicines suggested to be of therapeutic utility for pathological conditions different from their original design ("repositioning"). Here, we overview the most recent studies on Dimebon directed to pathological processes in the brain-involving in vivo models of proteinopathies. In the latter, neurodegenerative effects are attributed to a group of aggregate-prone proteins such as γ-synuclein, hyperphosphorylated tau, and fused in sarcoma (FUS), which are engaged in numerous neurological diseases. We also focus on in vitro models comprised of cultured SH-SY5Y neuroblastoma cells expressing mutant forms of transactive response DNA binding protein 43 kDa (TDP-43) and showing a reduced number of TDP-43 inclusion-containing cells upon Dimebon treatment along with activation of autophagy markers. Finally, we discuss Dimebon's action in improving cellular energy balance, stabilizing mitochondrial function by increasing the threshold for nonselective mitochondrial pore opening, as well as increasing the calcium retention capacity of mitochondria and reducing lipid peroxidation. Our results, together with data from other laboratories, warrant re-evaluation of the therapeutic potential of Dimebon and its newly designed analogs as promising disease-modifying agents to treat neurodegenerative disorders. Further, emerging data favor a possible anti-aging effect and application of Dimebon for the treatment of depression, anxiety, and ischemia. The most pronounced effect of Dimebon is observed when treatment starts early in disease onset. This is a major factor which needs to be taken into account when planning future clinical trials.
AuthorsAleksey Ustyugov, Elena Shevtsova, Sergey Bachurin
JournalMolecular neurobiology (Mol Neurobiol) Vol. 52 Issue 2 Pg. 970-8 (Oct 2015) ISSN: 1559-1182 [Electronic] United States
PMID26123670 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • DNA-Binding Proteins
  • Excitatory Amino Acid Antagonists
  • FUS protein, human
  • Indoles
  • Nerve Tissue Proteins
  • Neuroprotective Agents
  • RNA-Binding Protein FUS
  • Recombinant Fusion Proteins
  • TARDBP protein, human
  • latrepirdine
Topics
  • Animals
  • Autophagy (drug effects)
  • DNA-Binding Proteins (chemistry, drug effects)
  • Excitatory Amino Acid Antagonists (pharmacology)
  • Female
  • Humans
  • Indoles (pharmacology, therapeutic use)
  • Mice
  • Mutation
  • Nerve Tissue Proteins (metabolism)
  • Neurodegenerative Diseases (drug therapy)
  • Neuroprotective Agents (pharmacology, therapeutic use)
  • Protein Aggregation, Pathological (drug therapy)
  • RNA-Binding Protein FUS (genetics)
  • Recombinant Fusion Proteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: